REGENXBIO

Securities lawsuit filed against $RGNX alleging misleading statements about RGX-111 gene therapy. Eligible investors must act before April 14, 2026 deadline.

Class actions filed against $PYPL over false revenue projections and $RGENX after FDA clinical hold on gene therapy following safety concerns.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Rosen Law Firm files securities class action against REGENXBIO for alleged false statements on product safety and efficacy, with April 14, 2026 lead plaintiff deadline.

Class action lawsuit filed against $REGENXBIO alleging false statements on RGX-111 gene therapy. Covers investors from February 2022 to January 2026.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

REGENXBIO faces class action lawsuit over RGX-111 gene therapy trial disclosures. Lead plaintiff deadline is April 14, 2026.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.